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Abstract Antiretroviral therapy alters lipid metabolism in
HIV-infected patients. However, interpreting the impact of
HIV infection on lipid metabolism is difﬁcult because of
various associated factors, including antiretroviral drugs and
demographic characteristics. A few studies have associated
HIV infection with lipid metabolism in antiretroviral-naı¨ve
HIV-infected patients. Because there were no data in this
regard from Japan, the present study examined the impact of
HIV infection, as well as demographic and clinical features,
on lipid metabolism in antiretroviral-naı¨ve HIV-infected
patients in Japan. We performed a cross-sectional study to
examine the impact of HIV disease, demographic and clin-
ical characteristics on lipid metabolism among 168 HIV-
infected Japanese men who were antiretroviral naı¨ve and
who did not have hemophilia, including patients who took
medication for dyslipidemia. The mean age of the patients
was 45.7 years; 0.6% of the patients took medication to
dyslipidemia. The mean CD4 lymphocyte count was
289/lL, the mean baseline log10 HIV viral load was 4.2
HIV-1 RNA copies/mL, and 22% of the patients had a his-
tory of AIDS-deﬁning events. A higher HDL-C concentra-
tion was associated with a higher CD4 lymphocyte
count (p = 0.043). Also, a higher LDL-C concentration was
associated with a higher CD4 lymphocyte count (p =
0.003). Infectionwith HIVwas associated with dyslipidemia
in antiretroviral-naı¨ve patients. More advanced HIV disease
was associated with less favorable lipid homeostatic proﬁles.
These results are similar to ﬁndings from other countries.
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Introduction
The current treatment has signiﬁcantly prolonged the survival
of patients infected with HIV. Accordingly, the frequencies
of not only opportunistic infection but also long-term meta-
bolic complications have increased. Several investigators
have reported that metabolic syndrome is more common in
HIV-infected patients than in HIV-negative individuals, and
altered lipid metabolism has also been reported since the start
of the HIV epidemic [1–7]. These outcomes have been
ascribed to antiretroviral therapy. Studies [8–11] have
demonstrated that high total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), and triglyceride (TG)
concentrations are associated with protease inhibitor (PI)
treatment. High TC and TG concentrations have also been
identiﬁed in patients on non-PI highly active antiretroviral
therapy (HAART) regimens.
Some studies have recently demonstrated that HIV
infection and demographic characteristics inﬂuence lipid
metabolism in patients who are antiretroviral naı¨ve
[12–15]. Low high-density lipoprotein cholesterol (HDL-C)
concentrations and hypertriglyceridemia have been detec-
ted in antiretroviral-naı¨ve HIV-infected patients who do
not have a history of antiretroviral therapy. However,
participants in these studies were derived from predomi-
nantly one or two ethnic groups. The impact of HIV
infection on lipid metabolism has never been studied in a
Japanese population.
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The present study determines the impact of demographic
and HIV disease characteristics on lipid metabolism in
antiretroviral-naı¨ve HIV-infected patients in a Japanese
population.
Patients and methods
Patient population
A total of 218 HIV-infected nonhemophilic patients were
treated at Juntendo University Hospital in Tokyo, Japan
between October 1992 and March 2010. We retrospec-
tively reviewed their records and selected 168 Japanese
male patients from among them, including patients who
took medication for dyslipidemia. Thirty-two patients were
excluded because antiretroviral therapy was started at
another institution and information about their status before
that point was unavailable. Also, 17 patients who were
female or not Japanese were excluded.
Patients were eligible if they had evidence of HIV
infection, in the form of either positive Western blot
ﬁndings or measurable plasma HIV-1 RNA. The Research
Ethics Committee of Juntendo University School of
Medicine approved the study protocol.
Assessments and measurements
After we obtained their histories, the patients underwent
a baseline physical examination to ascertain demographic
and clinical characteristics, HIV risk factors, previous
HIV disease-related diagnoses, and current medications.
Height and weight were measured following a standard
procedure, and body mass index (BMI) was calculated
as weight in kg/height in m2. We tested for HIV anti-
body using a chemiluminescence enzyme immunoassay
(CLEIA).
Venous blood was drawn from all of the patients, and
then concentrations of HDL-C or LDL-C were calculated
using the Friedewald formula. The most recent blood data
were obtained from patients who had never received anti-
retroviral therapy, and just before initiating antiretroviral
therapy from those who had.
Statistical methods
Descriptive statistics are reported as mean values with
standard SD and median values. Lipid parameters were
compared between patients with or without AIDS-deﬁning
events using the Mann–Whitney U test and the unpaired
t test. Correlations of HIV RNA level and CD4 cell
counts with lipid parameters were assessed by linear
analysis.
The level of statistical signiﬁcance was deﬁned as
p\ 0.05, and all data were analyzed using JMP version 8
(SAS Institute Inc.).
Results
Patient population
Of the 168 patients included in this analysis, 27% (17/63)were
smokers, 1.8% (3/168) had diabetes, and 0.6% (1/168) had a
history of intravenous drug use. 0.6% (1/168) of the patients
took medication for dyslipidemia. 60% (100/168) of the
patients took antiretroviral therapy that generally consisted of
two nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) plus either one non-nucleoside reverse transcriptase
inhibitor (NNRTI) or a PI (with orwithout ritonavir boosting),
following the guidelines for the use of antiretroviral agents in
HIV-1-infected adults and adolescents [16].
The mean age was 45 ± 13 years (mean standard
deviation; SD), and 22% (37/167) had AIDS-deﬁning
events. The mean baseline CD4 lymphocyte count was
289 ± 249/lL, and the mean baseline log10 HIV RNA
was 4.2 ± 0.7 HIV-1 RNA copies/mL (Table 1).
Lipid parameters and demographic characteristics
compared according to HIV stage
Patients were assigned for comparisons to paired groups
with or without AIDS-deﬁning events (Table 2). There is
Table 1 Patient characteristics
Factor n Mean ± SD
Age (years) 167 45.7 ± 13.2
BMI (kg/m2) 130 22.0 ± 3.3
TC (mg/dL) 145 155 ± 35.2
LDL-C (mg/dL) 43 92.2 ± 27.7
HDL-C (mg/dL) 54 38.6 ± 12.4
HIV RNA level (log copies/mL) 148 4.2 ± 0.70
CD4 (cells/lL) 164 289 ± 249
Factor n Number
(weighted %)
HIV treatment history 168 100 (59.5)
AIDS-deﬁning event (yes) 167 37 (22.2)
MSM 133 97 (72.9)
Drugs 168 1 (0.6)
Smoker 63 17 (27)
DM 168 3 (2.9)
BMI body mass index, TC total cholesterol, LDL-C low-density
lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol,
MSM men who have sex with men, DM diabetes mellitus
Value are means ± SD and number (weighted %)
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no signiﬁcant difference in lipid proﬁle between patients
with AIDS and those without AIDS.
Higher concentrations of HDL-C and LDL-C were
associated with a higher CD4 lymphocyte count. However,
HIV RNA levels were not associated with the lipid proﬁle,
and CD4 lymphocyte counts were not associated with TC
concentrations (Figs. 1, 2).
Discussion
This study demonstrated the impact of HIV diseases on lipid
metabolism in antiretroviral-naı¨ve patients selected from the
Japanese male population. The relationships between the
markers of HIV infection and lipid parameters in this study
were consistent with those of previous reports based on other
ethnic populations [12–15]. Patients with lower CD4 lym-
phocyte counts were more likely to have lower LDL-C and
HDL-C levels. A recent study found that HIV seroconver-
sion is associated with decreased TC, HDL-C and LDL-C
concentrations [17]. Constans et al. [18] suggested that the
alterations in cholesterol metabolism that occur in HIV-
infected patients could be explained by lipid peroxidation.
The cytokine tumor necrosis factor (TNF)-a plays a role in
plasma lipoprotein peroxidation in HIV-infected patients by
stimulating the production of reactive oxygen species [19].
These modiﬁcations might have major effects on the
immune system.
A low HDL-C concentration increases the risk for coro-
nary artery disease [20–22]. Others have found that a lower
HDL-C concentration is associated with a higher risk of
cardiovascular disease (CVD) in HIV-infected patients in
US and European populations [23, 24]. However, no such
study had previously been performed for a Japanese popu-
lation. The HDL-C concentration of HIV-infected patients
in this study (38.6 ± 12.4 mg/dL) was\51 mg/dL, which is
considered to indicate an increased risk for CVD [25]. There
is evidence for relationships between BMI and age to HDL-
C concentration [26, 27]. However, small sample size lim-
ited our ability to assess causal relationships in this study.
Table 2 Comparison of the characteristics of patients with or without AIDS-deﬁning events
Baseline factor n With AIDS-deﬁning
events (n = 37)
Without AIDS-deﬁning
events (n = 130)
p value *Difference *p value
TC (mg/dL) 145 152.3 ± 35.1 156.5 ± 35.3 0.549b 2.32 0.2347
LDL-C (mg/dL) 43 99.5 ± 8.33 89.7 ± 4.89 0.315b -2.09 0.4733
HDL-C (mg/dL) 54 32.0 ± 10.5 39.9 ± 12.4 0.79a 2.17 0.1326
BMI body mass index, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG
triglyceride, DM diabetes mellitus
Value are means ± SD and number (weighted %). Determined by athe Mann–Whitney U test and bthe unpaired t test
* Adjusted by BMI, age
Fig. 1 Correlation of lipid measures with the CD4? cell count
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Numerous studies have implicated antiretroviral ther-
apy, and in particular PIs, as an important risk factor for
metabolic syndrome including dyslipidemia when con-
trolling for other demographic and traditional risk fac-
tors. On the contrary, Mondy et al. [5] showed that
metabolic syndrome is closely associated with traditional
risk factors rather than with antiretroviral therapy-related
effects. Therefore, these and the present ﬁndings suggest
that the assessment of lipid parameters is an essential
component of routine clinical care for HIV-infected
patients.
This study has some limitations. The cross-sectional
study design and small sample size limited the ability to
assess causal relationships between HIV diseases and lipid
parameters. Antiretroviral therapy has signiﬁcantly pro-
longed the survival of HIV-infected patients, and only
lately has more attention has been directed toward long-
term metabolic syndrome. Therefore, the lipid data set we
obtained was rather small. We also could not always ensure
overnight fasting when we took a blood sample because of
the retrospective study design. Finally, whether or not lipid
data was taken during the treatment of the HIV-infected
patient depended on the doctor’s subjective judgement,
suggesting potential biases.
In conclusion, the present ﬁndings indicate that HIV
disease itself is associated with lipid metabolism in anti-
retroviral-naı¨ve patients in the Japanese male population.
More advanced HIV disease was also associated with an
unfavorable lipid proﬁle. Antiretroviral therapy, together
with the stage of HIV disease as well as demographic and
clinical characteristics, should be considered when inter-
preting dyslipidemia in HIV-infected patients.
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